Clinical Psychopharmacology Education For Prescribers

Recent articles and videos

Cannabis: Currently Approved Indications and Therapeutic Potential

Dr. Paul Morrison Clinical Senior Lecturer Institute of Psychiatry King’s College London NHS Consultant Psychiatrist The Maudsley Hospital, London       This presentation reviews indications for currently approved cannabis products (dronabinol and nabilone). It also discusses the therapeutic potential of CBD in psychiatry (psychosis) and other medical conditions (epilepsy, oncology). In this section, we’ll…

Trazodone for Disturbed Sleep Initiation in PTSD

David N. Osser, MD Associate Professor of Psychiatry Harvard Medical School Brockton Division of the VA Boston Healthcare System In this video, Dr. David Osser reviews the evidence base for the use of trazodone in PTSD patients with disturbed sleep initiation. He also comments on side effects, with a focus on priapism. This video is…

Understanding Cannabis in Psychiatry: Pharmacology and Synthetic Cannabinoids

Dr. Paul Morrison   Clinical Senior Lecturer Institute of Psychiatry King’s College London   NHS Consultant Psychiatrist The Maudsley Hospital, London     This presentation discusses cannabinoid pharmacology and synthetic cannabinoids. The endocannabinoid system consists of: CB1 and CB2 receptors, anandamide, 2‐arachidonoylglycerol (2-AG). Regarding synthetic cannabinoids, they are CB1 full agonists and their effect is…

Antipsychotics News: Cariprazine, Risperidone and New Drug Applications

Author: Flavio Guzman, MD Editor Psychopharmacology Institute Dr. Guzman has no conflicts of interest to disclose. Cariprazine for Negative Symptoms of Schizophrenia: The FDA Refuses to Review Supplemental New Drug Application (sNDA) The FDA has refused Allergan’s request to review a Supplemental New Drug Application (sNDA) to expand the approved uses to include negative symptoms of schizophrenia…

Buprenorphine for Opioid Use Disorder: Mechanism of Action

By Joji Suzuki, MD Director, Division of Addiction Psychiatry Department of Psychiatry Brigham and Women’s Hospital Assistant Professor of Psychiatry Harvard Medical School This presentation reviews the mechanism of action of buprenorphine in the treatment of opioid use disorders. Dr. Suzuki explains how partial agonism and high affinity for mu opioid receptors increases the risk of…

Comments on the 2017 VA/DoD Practice Guideline for the Management of PTSD

By: David Osser, MD; Flavio Guzman, MD In June 2017, the U.S. Department of Veterans Affairs and the Department of Defense published a new edition of the Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. After we published a video lecture (Faculty: David Osser, MD , Harvard Medical School) on…

Prazosin for PTSD-Related Nightmares: Rationale and Dosing Strategies for Men and Women

David N. Osser, MD Associate Professor of Psychiatry Harvard Medical School Brockton Division of the VA Boston Healthcare System In this video, Dr. David Osser explains the rationale behind the recommendation of using prazosin as first-line treatment for PTSD-related nightmares and disturbed arousals. He also gives practical advice on different dosing strategies for men and…

Buprenorphine Formulations: A Practical Summary for Clinicians

Joji Suzuki, MD Director, Division of Addiction Psychiatry Department of Psychiatry, Brigham and Women’s Hospital Assistant Professor of Psychiatry, Harvard Medical School This presentation discusses current buprenorphine formulations available for the treatment of opioid use disorder and the rationale for the buprenorphine/naloxone combination. One important concept to remember is that the combination tablet containing both…

The Neurobiology of Behavioral and Psychological Symptoms of Dementia: An Illustrated Update

Author: Rajesh Tampi, MD Behavioral and psychological symptoms of dementia (BPSD) include a heterogeneous range of psychological reactions, psychiatric symptoms and behaviors. This presentation discusses the neurobiology of BPSD by addressing anatomical, biochemical and functional changes associated with this group of symptoms. BPSD tends to occur because of a complex interaction between anatomical, functional, and…

Psychopharmacology of Sleep and Wakefulness: Understanding Neurotransmitters and Pathways in Clinical Practice

Author: Flavio Guzman, MD This tutorial integrates neurotransmitters involved in sleep and arousal with the pharmacology of specific psychotropic agents. We review neurotransmitters that promote wakefulness (dopamine, norepinephrine, serotonin, acetylcholine, histamine, orexin/hypocretin) and summarize how current drugs influence each system. We also discuss neurotransmitters that promote sleep (adenosine, GABA, melatonin). This is an integration between…

PDF: LAI Antipsychotics

Screenshot_2017-01-07_12.39.54

Free PDF Download

  • New formulations (Aristada, Invega Trinza)
  • Practical dosing tables
Powered by ConvertKit